An innovative home monitoring AI platform, enables patients, their families and care providers to improve the management of multiple respiratory chronic diseases
 
 
Clinical Problem / Unmet Need
COPD is a chronic lung and airways disease in which the airways are constricted, making it difficult to breathe. It is the 4th cause of death in the world the 3rd in the US. It's caused by long-term exposure to irritating gases or particulate matter, often from cigarette smoke.

People with COPD are likely to experience episodes called exacerbations, during which the lung will experience the tightening of airway passages and inflammation triggered by the activation of the body's immune defenses. The most common cause of death occurs after a COPD exacerbation. Roughly 10% of patients will die during the hospital stay and the 2-year mortality rate following hospitalization is about 50%.

There is a clear unmet need to develop a clinically useful home monitoring disease management tool that will enable:
  • Early detection of disease exacerbations
  • Monitor disease status continuously
  • Follow and control patient medication adherence
  • Save patients live and high costs to the healthcare system
  • Proposed Solution
    RespirAI develops a game-changing, home-monitoring AI platform with a mission to detect early exacerbations of chronic diseases, while enabling patients, their families, and care providers to improve the disease management thus improving patients' quality of life. RespirAI platform includes a chest patch, capture medical physiological data, and an application, which monitor the patients’ disease status.

    The core technology of the system is based on an invention of researchers from the University of Nebraska at Omaha who developed a novel home monitoring wearable device, which leverages artificial intelligence (AI) capabilities to early detect COPD exacerbations before they happen.

    For more information:
    https://www.respirai.com/
    Nimrod Bin-Nun
    RespirAI CEO
    nimrod@respirai.com
    Assaf Gur
    RespirAI CTO
    assaf@respirai.com
    More Projects Funded
    eHealth Ventures by Numbers:
    15
    Portfolio Companies
    1400
    Companies Reviewed
     
     
    115
    Years of experience for 4 principles
     
    7
    X
    Fair Value Appreciation on Portfolio
    Partners & Collaborators